Authors' Perspective on the International Society for Heart and Lung Transplantation Consensus Statement on Risk Stratification in Pulmonary Arterial Hypertension

Bayer, Janssen Biotech, Jucabio, Keros Therapeutics, Respira Therapeutics, and United Therapeutics Corporation. Leadership roles on the Board of Directors for the International Society of Heart and Lung Transplantation and the Scientific Advisory Board of United Therapeutics. Her spouse is a Senior Director in Clinical Development at Intellia Therapeutics. FH: Research funding for investigator-initiated study by Janssen on computational approaches to surrogate end-point research in pulmonary hypertension. YH: None. AH: Research grants from NIH/NHLBI. Consultation fees from Gossamer Bio, United Therapeutics, Merck, and Janssen. MHH: Consulting fees from Acceleron, Actelion, AOP Health, Bayer, Ferrer, Gossamer Bio, Inhibikase, Janssen, Keros, MSD, and Novartis. Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or educational events from Actelion, AOP Health, Bayer, Ferrer, Janssen, and MSD. MKK: None. DL: Consulting or advisory and speaking and lecture fees from United Therapeutics. SM: None. KMO: Consultant or speaker for Acceleron, Actelion, AOP Orphan, Bayer Healthcare, Ferrer, Gossamer Bio, Janssen Global Services, and Merck. IP: Research grants paid to her institution by United Therapeutics, Merck, Keros, and Janssen. Consulting fees from United Therapeutics, Respira Therapeutics, Merck, Liquidia, Keros, Janssen, Insmed, and Gossamer Bio. Advisory Board member for Aerovate, Altavant. Steering Committee member for Acceleron. DMC Chair for Tectonic Therapeutic. GR: Research grants paid to his institution from Acceleron, Actelion, Bayer, GlaxoSmithLkine, Janssen, Merck, Pfizer, United Therapeutics, and Novartis. Consulting or advisory for Actelion, Bayer, GlaxoSmithKline, Janssen, and Nordic Infucare. OS: Research grants paid to his institution from Aerovate, AOP Orphan, Ferrer, Janssen, and Merck. Consulting fees from Altavant/Enzyvant, AOP Orphan, Ferrer, Gossamer Bio, Janssen, Liquidia, Merck, Respira Therapeutics, Roivant Sciences, and United Therapeutics. Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Aerovate, AOP Orphan, Janssen, Ferrer, and Merck. Participation on a Data Safety Monitoring Board or Advisory Board for Altavant/Enzymant, Gossamer Bio, Janssen, and Respira Therapeutics. MGT: None. JLV: Consulting fees from Gossamer Bio, Liquidia, Pulmovant, Keros, Johnson & Johnson, and Merck. RV: None. JW: Research grants paid to his institution from Janssen, 35Pharma, Merck, Astra Zeneca, and Sanofi. Consulting fees from Janssen, Merck, and Apollo. Payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing, or education events from Janssen and Merck. Payment for expert testimony from Sprigings Intellectual Property Law. Support for attending meetings and/or travel from Janssen and Merck. Participation on a Data Safety Monitoring Board or Advisory Board from Janssen, Merck, Universite Laval, Cambridge University. Leadership roles in the Pulmonary Hypertension Association of Canada and the Pulmonary Vascular Research Institute. RJW: Research grants paid to his institution from United Therapeutics, Merck, Gossamer, and Liquidia. Consulting fees from Merck. Support for attending meetings and/or travel from United Therapeutics. HW: None. MW: Consulting fees from United Therapeutics, Actelion, Bayer, and Janssen. Speaking fees from United Therapeutics, Actelion, and Bayer. Travel reimbursement from United Therapeutics and Actelion. RB: Research grants paid to his institution from Actelion, Bayer, Bellerophon Therapeutics, and Eiger Biopharmaceuticals. Consulting fees from Abbott, Bayer, and United Therapeutics.